Private Advisor Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Private Advisor Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-600	Closed	-$154K	–	2833
2026 Q1	$154K	Sell	600 -200	-25%	-$153K	﹤0.01%	2490
2025 Q4	$208K	Sell	800 -900	-53%	-$611K	﹤0.01%	2378
2025 Q3	$164K	Buy	1,700 +700	+70%	+$396K	﹤0.01%	2364
2025 Q2	$102K	Buy	+1,000	New	+$558K	﹤0.01%	2316
2021 Q1	–	Sell	-200	Closed	-$23K	–	1958
2020 Q4	$23K	Buy	+200	New	+$108K	﹤0.01%	1743

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Private Advisor Group's REGN Position: Q2 2026 in Review

Private Advisor Group increased its Regeneron Pharmaceuticals (REGN) stake by 7.2% in Q2 2026, buying an estimated $845K and bringing the position to 18,557 shares worth $11.6M. The position accounts for 0.05% of the portfolio, ranked #352.

Private Advisor Group first reported a position in REGN in Q2 2015 and has held it in 45 quarters since. The position peaked at $13.7M in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Private Advisor Group held 18,557 shares of Regeneron Pharmaceuticals worth $11.6M as of Q2 2026.
Private Advisor Group bought 1,242 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $845K.
Regeneron Pharmaceuticals made up 0.05% of Private Advisor Group's portfolio in Q2 2026, its #352 holding.
Private Advisor Group first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 45 quarters since.
Private Advisor Group's Regeneron Pharmaceuticals position peaked at $13.7M in Q4 2025.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.